Skip to search formSkip to main contentSkip to account menu

CEP-18770

Known as: CEP 18770, Proteasome Inhibitor CEP 18770 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

delanzomib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
[Proteasome inhibitors in cancer therapy].
Proteasomes are multisubunit enzyme complexes. They contain three enzymatic active sites which are termed chymotrypsin-like… 
2013
2013
Synthesis of Novel Potential Proteasome Inhibitors Based on Tripeptide Backbone
O-Benzyl-5-chlorsalicyl-tripeptide aldehydes are novel organic compounds aimed for inhibition of the proteasome. The inhibition… 
Review
2011
Review
2011
Second-Generation Proteasome Inhibitors
The first-in-class proteasome inhibitor, bortezomib, has provided proof-of-concept for the therapeutic approach of proteasome… 
2009
2009
Combination therapies for the treatment of multiple myeloma in combination with cep-18770 and bortezomib or melphalan
The present invention includes the step of co-administering the compound 1 and bortezomib subject, provides a method of treating… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)